Neurotrope
205 East 42nd Street, 16th Floor
New York
New York
33324
United States
Tel: 973-242-0005
Website: http://www.neurotropebioscience.com/
109 articles about Neurotrope
-
Synaptogenix Schedules Business Update Conference Call
12/15/2020
Synaptogenix, Inc. (OTC: SNPX), formerly Neurotrope Bioscience, Inc., announced the successful spin-off of substantially all of the legacy assets and liabilities of Neurotrope, Inc. last week. The Company plans to hold an audio conference call for investors on Tuesday, December 15, 2020 at 4:15 p.m. ET to provide a general business
-
Neurotrope and Metuchen Pharmaceuticals Announce Completion of Merger Forming Petros Pharmaceuticals
12/2/2020
Neurotrope, Inc. (Nasdaq: NTRP) and Metuchen Pharmaceuticals, L.L.C., a privately held biopharmaceutical company focused on innovative therapeutics for men's health conditions ("Metuchen"), today announced the completion of their previously announced merger following the satisfaction of all closing conditions required by the amended merger agreement (the "Merger Agreement").
-
Neurotrope, Inc. Approves Spin-Off of Neurotrope Bioscience, Inc. and Sets Record and Distribution Dates
11/20/2020
Neurotrope, Inc. (NASDAQ: NTRP) ("Neurotrope" or the "Company") announced today that its Board of Directors has approved the conditional distribution and set the shareholder of record and distribution dates in connection with the previously announced spin-off (the "Spin-Off") of its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI").
-
Neurotrope Announces First Patient Dosed in Long-Term Clinical Trial of Bryostatin in Alzheimer's Disease
10/6/2020
Neurotrope, Inc. (Nasdaq: NTRP) today announced dosing of the first patient in its ongoing, long-term Phase 2 study of Bryostatin-1 for the treatment of Alzheimer's disease ("AD").
-
Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement with Metuchen
9/30/2020
Neurotrope Shareholders, Currently Representing 34 Percent of Shares Outstanding, Sign Agreement in Support of Merger Petros to Grow Stendra® and Explore Non-Prescription / Over-the-Counter Strategies for Stendra® in Partnership with Foundation Consumer Healthcare, a Juggernaut Capital portfolio investment and One of the Largest Pure-Play OTC Companies in the U.S. Company to be Led by Fady Boctor as President and Chief Commercial Officer. John Shulman, Founder and Managing Pa
-
Neurotrope Bioscience Announces Agreement with Worldwide Clinical Trials, to Conduct Ongoing Phase 2 Study of Bryostatin-1, Partially Funded by NIH, for Alzheimer's Disease
7/30/2020
Neurotrope, Inc. (Nasdaq: NTRP) ("Neurotrope" or the "Company") today announced that its wholly-owned subsidiary, Neurotrope Bioscience, Inc. ("NBI"), has entered into a services agreement with Worldwide Clinical Trials ("WCT") to support site recruitment and activation for the Company's ongoing Phase 2 study of bryostatin-1 in the treatmen
-
Neurotrope Announces Strategic Partnership with BryoLogyx for Supply of Synthetic Bryostatin-1 and Continuation of the National Cancer Institute (NCI) Trial for Childhood Leukemia
6/10/2020
- Neurotrope and Metuchen continue to move toward closing the previously announced merger -Two separate publicly listed companies result: men's health company, Petros Pharmaceuticals, Inc. and Bryostatin-1 neurological disease company, Neurotrope Bioscience, Inc.
-
BryoLogyx Announces Agreements with Neurotrope to Acquire Bryostatin-1 Immuno-Oncology Data Package, Supply Synthetic Bryostatin-1
6/10/2020
Agreements will Accelerate BryoLogyx’s Path to Clinical Proof-of-Concept Study GMP-Certified Bryostatin-1 to be Synthesized by Albany Molecular Research Inc. DANVILLE, Calif.--( BUSINESS WIRE )-- BryoLogyx Inc. today announced it has entered into two agreements with Neurotrope, Inc. (Nasdaq: NTRP) to acquire Neurotrope’s preclinical data package and drug product for use of bryostatin-1 in an immuno-oncology application, and to supply Neurotro
-
Clinical Catch-Up: May 25-29
6/1/2020
In the lead-up to the ASCO Annual Meeting, companies were presenting some of their trial data, while other companies were presenting news related to COVID-19 studies. Here’s a look. -
Neurotrope Launches New Long-Term Clinical Trial of Bryostatin with the National Institutes of Health for the Treatment of Patients with Alzheimer's Disease
5/28/2020
- New Phase 2 Study to Be Conducted in Collaboration with NIH Under a $2.7 Million Grant - - Management to Host Investor Conference Call and Webcast Today at 11:00 AM ET -
-
The Phase II study will be performed in collaboration with the National Institutes of Health under a $2.7 million grant.
-
Neurotrope Announces Investor Update Conference Call
5/26/2020
Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc.
-
Neurotrope and Metuchen Pharmaceuticals Announce Merger Agreement to Form Petros Pharmaceuticals, a Men's Health Company
5/18/2020
Lead asset Stendra® (avanafil) Looks to Build on $25 Million of 2019 Gross Sales Disruptive pipeline opportunity with topical treatment for Peyronie's disease Neurotrope Bioscience, Inc. will continue as a separately traded entity with its lead Bryostatin program treating neurodegeneration Charles S. Ryan, J.D., Ph.D. named President and Chief Executive Officer of Petros
-
Petros will be helmed by Charles S. Ryan, who currently serves as chief executive officer of Neurotrope.
-
Clinical Catch-Up: Jan 20-24
1/27/2020
The week after the JP Morgan Healthcare Conference tends to be slower than the week of, and last week was no outlier. Still, there were clinical trial updates. Here’s a look. -
Neurotrope, Inc. Announces $18 Million Registered Direct Offering
1/22/2020
Neurotrope, Inc. (the "Company") (NASDAQ:NTRP) today announced that it has received commitments from institutional investors and pre-existing high net worth individuals to purchase an aggregate of $18 million of the Company's securities in a registered direct offering.
-
Neurotrope Announces Review of Strategic Alternatives to Maximize Shareholder Value
10/8/2019
Neurotrope, Inc. (Nasdaq: NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, today announced its plans to explore strategic alternatives to maximize shareholder value.
-
Clinical Catch-Up: September 9-13
9/16/2019
Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories. -
Neurotrope Announces Top-line Results From Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease
9/9/2019
An average increase in SIB total score of 1.3 points and 2.1 points was observed for the Bryostatin-1 and placebo groups, respectively, at Week 13.
-
Neurotrope announced that its Phase II trial of Bryostatin-1 in moderate to severe Alzheimer’s disease did not show statistical significance on the primary endpoint, change from baseline to Week 13 in the Severe Impairment Battery (SIB) total score.